Abstract: The invention provides a syringe accessory device for adjustment of a predefined partial syringe dosage comprises a recess (10) for receiving a syringe body (14). Additionally, within a single portion (12) a slot (16) is located. Within the slot (16) a syringe flange (18) or finger grip can be held. To obtain a predefined dosage of liquid within the chamber of the syringe body (14), a plunger (26) is pressed in the chamber (14) in the direction of the arrow (38) until the plunger head (44) contacts a stopping means (24) whereby the stopping means is performed by a stopping surface (24) of the single portion (12). The invention further provides a kit comprising said syringe accessory device and its use for adjusting defined liquid dosages in syringes.

Abstract: The present invention relates to the combination of antigens directed against bacteria and viruses, their uses and the preparation of medicaments in order to confer protection against infectious diseases. In particular, the invention relates to a combination vaccine comprising at least one antigen of Clostridium tetani, at least one antigen from Corynebacterium diphtheriae, and at least one antigen from the TBE-flavivirus suitable to confer seroprotection against diseases and medical conditions caused by these pathogenic organisms.

Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus 5 culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.

Abstract: Novel processes for the replication of influenza viruses in cell culture, and vaccines and diagnostic compositions which contain the influenza viruses obtainable by the process or constituents thereof, are described.

Abstract: The present invention relates to a culture medium for disperse mycobacteria comprising at least one detergent and an antifoam agent, whereby said antifoam agent is a member of the silicone family. In addition, the invention provides for methods for the activation of dipressed mycobacteria, for obtaining a standardized mycobyterial culture or for the production of (a), purified protein derivates(s) (PDD) which comprise the cultivation of mycobacteria in the active medium disclosed herein. Furthermore, the use of standardized mycobacterial cultures obtained by the method of the invention for the preparation of pharmaceutical or diagnostic compositions is described.

Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.

Abstract: The present invention concerns methods for multiplication of viruses in cell culture in which cells are infected with a virus and after infection the cells are cultured in cell culture under conditions that permit multiplication of the viruses and at the same time targeted additional, at least two-fold, multiplication of the cells. The invention also concerns the use of the viruses so obtained or proteins expressed by them for production of drugs and diagnostic agents.

Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.

Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium.

Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.

Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Abstract: The invention relates to preparation of selected peptides of the HIV gag protein and derivatives thereof which comprise the peptide sequence NPGLLETSEGCRQ, and which inhibit HIV.